source
- Ibrutinib monotherapy shows ten-year durable efficacy across CLL subtypesIbrutinib monotherapy has demonstrated lasting effectiveness in chronic lymphocytic leukemia across multiple disease subtypes. Data reveal that patients, including those with TP53 mutations, maint…
- Create Medicines secures $122M Series B to advance in vivo CAR-T therapiesCreate Medicines, a Cambridge biotech, announced a $122 million Series B financing to expand its in vivo CAR-T cell therapy platform targeting cancer and autoimmune diseases. The round was co-led…